Fig. 2: TNKS inhibition restrains lipolysis-associated proteins, induces browning of WAT and increases adiponectin level in WAT, and serum in db/db mice.
From: Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice
Representative immunoblot (a) and quantification (b) of ATGL and phospho-HSL in WAT of G007-LK-treated and control mice. c qRT-PCR analyses of UCP-1 and PGC-1α transcripts in WAT of db/db mice (A.U., arbitrary unit). Representative immunoblot (d) and quantification (e) of UCP-1 and PGC-1α in WAT of G007-LK-treated and control db/db mice. f–i Representative immunoblots (f, h) and corresponding quantifications (g, i) of adiponectin (AdipQ) in WAT (f, g) and serum (h, i) of G007-LK-treated and control mice after 15 weeks of treatment. The graphs represent quantifications of the indicated proteins normalized to actin (b, e, g, and l) or quantification of the individual bands on the blots (i). Error bars represent ±SEM. One-way ANOVA with Bonferroni adjustment for multiple comparisons, two-tailed t-test. *p < 0.05; **p < 0.01. In WAT (a–g), control n = 4–7; G007-LK n = 5–8, in serum (h, i), control n = 5; G007-LK n = 6.
